Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07005713) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria' on May 22.

Brief Summary: This study is a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of BGB-16673 in adults with chronic spontaneous urticaria (CSU).

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Chronic Spontaneous Urticaria

Intervention: DRUG: BGB-16673

Administered orally

DRUG: Placebo

Administered orally ...